Alfredo Berruti, MD, on Adrenocortical Carcinoma: Preliminary Study Results With Adjuvant Mitotane

February 22, 2022 By The ASCO Post Staff

Alfredo Berruti, MD, of Italy’s University of Brescia, discusses the first study to give adjuvant mitotane to patients with adrenocortical carcinoma, a rare disease with a high risk of relapse after radical surgery. Although theoretically this treatment may be clinically worthwhile, the findings suggest that the need for adjuvant mitotane should always be discussed on a case-by-case basis by the multidisciplinary team, and more study is warranted (Abstract 1).

Related Content